Ebos Group logo

Ebos Group(ASX) EBO

Market CapA$3.39BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)+217%
5 Year-40%
1 Year-34%
1 Month-7%
A$16.40
+0.86%
+0.14Today
Ebos Group last closing stock price
MetricPriceDate
Last closeAUD 16.402026-09-11
Ebos Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.96%AUD 16.902026-09-04
1 month-7.2%AUD 17.672026-08-12
3 month-3.93%AUD 17.072026-06-12
Year to date-26.61%AUD 22.352025-12-31
1 year-33.83%AUD 24.782025-09-11
3 year-42.38%AUD 28.462023-09-12
5 year-39.75%AUD 27.222021-09-10
Since inception+216.95%AUD 5.132013-12-06

Ebos Group Financials at a Glance

Market Cap

A$3.39BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$25.49B

Net Income (TTM)

A$435.83M

EPS (TTM)

A$1.09

P/E Ratio

14.94

Dividend

A$1.02

Beta (Volatility)

-0.00 (Low)

Price

A$16.40

Volume

98,269

Open

A$16.27

Previous Close

A$16.40

Daily Range

A$16.15 - A$16.46

52-Week Range

A$15.66 - A$26.70

Estimated Earnings Date

Feb 23, 2027

EBO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ebos Group

Ebos Group Limited is a leading provider of healthcare, medical, pharmaceutical, and animal care products across Australia, Southeast Asia, and New Zealand. The company operates through two main segments: Healthcare and Animal Care, offering a wide range of products and services to meet diverse market needs.

Products and Services
  • Healthcare logistics and medication management solutions
  • Pharmacy management software and consultancy services
  • Pet nutrition, grooming products, and veterinary supplies
Growth Outlook
  • Revenue of AUD 6.60 billion in the latest quarter, showing consistent growth
  • Net income of AUD 98.58 million, reflecting strong operational efficiency
  • Continued expansion in Southeast Asia and New Zealand markets
Financial Highlights
  • Trailing twelve months (TTM) revenue of AUD 25.83 billion
  • Dividend yield of 5.28%, indicating strong shareholder returns
  • Operating income margin of 2.85%, showcasing effective cost management
Ebos Group Limited has established itself as a key player in the healthcare distribution industry, with a robust portfolio of products and services. The company's recent financial performance highlights its ability to generate significant revenue and maintain profitability, making it an attractive option for potential investors. The focus on expanding into new markets and enhancing operational efficiencies positions Ebos Group for continued growth in the future.
AI Generated • Aug 23, 2026

Industry

Healthcare Providers and Services

Employees

6,200

CEO

Adam Luke Hall, MBA

Headquarters

Docklands, VIC 3008, AU

EBO Financials

Key Financial Metrics (TTM)

Gross Margin

7.09%

Operating Margin

2.80%

Net Income Margin

1.67%

Return on Equity

7.99%

Return on Capital

7.74%

Return on Assets

2.81%

Earnings Yield

6.69%

Dividend Yield

6.23%

Payout Ratio

58.73%

Stock Overview

Market Cap

A$3.39BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

207.00M

Volume

98.27K

Avg. Volume

121.92K

Financials (TTM)

Gross Profit

A$2.05B

Operating Income

A$863.23M

EBITDA

A$959.02M

Operating Cash Flow

A$764.79M

Capital Expenditure

-A$124.53M

Free Cash Flow

A$440.58M

Cash & ST Invst.

A$238.93M

Total Debt

A$1.90B

Ebos Group Performance Analysis

Ebos Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 12,237,401,00014.0%
20242024-06-30AUD 13,189,054,0007.8%
20252025-06-30AUD 12,266,898,000-7.0%
20262026-06-30AUD 13,486,684,0009.9%
Ebos Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-9.1%
Q42025-06-306.1%
Q22025-12-313.2%
Q42026-06-300.6%
Ebos Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD 1.3316.1%
20242024-06-30AUD 1.416.3%
20252025-06-30AUD 1.09-22.9%
20262026-06-30AUD 1.090.1%
Ebos Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-56.3%
Q42025-06-3089.3%
Q22025-12-3111.3%
Q42026-06-30-18.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$6.60B

+0.2%

Gross Profit

A$469.41M

-42.6%

Gross Margin

7.11%

N/A

Market Cap

A$3.39BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$547.56K

N/A

Employees

6,200

N/A

Net Income

A$98.58M

-27.0%

EBITDA

A$188.16M

-31.4%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$238.93M

+10.5%

Total Debt

A$1.90B

+15.9%

Accounts Receivable

A$1.60B

+16.9%

Inventory

A$1.39B

+15.1%

Long Term Debt

A$1.74B

+113.3%

Short Term Debt

A$151.51M

-81.5%

Return on Assets

2.81%

N/A

Return on Invested Capital

7.48%

N/A

Free Cash Flow

A$228.53M

+8.5%

Operating Cash Flow

A$299.74M

+23.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MSB.AXMesoblast Limited
A$2.15-0.92%
NEU.AXNeuren Pharmaceuticals Limited
A$20.25+0.20%
SNZ.AXSummerset Group Holdings Limited
A$6.60-2.22%
TLX.AXTelix Pharmaceuticals Limited
A$15.67-6.50%

Trending Stocks

Symbol / CompanyPricePrice Chg
KHCKraft Heinz
$24.60+0.01%
ACVAACV Auctions
$10.41+0.44%
TNONTenon Medical
$5.93+0.12%
ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF
$19.16+0.03%

Questions About EBO

What is the current price of Ebos Group?

Ebos Group is trading at A$16.40 per share.

What is the 52-week range for Ebos Group?

Over the past 52 weeks, Ebos Group has traded between A$15.66 and A$26.70.

How much debt does Ebos Group have?

As of the most recent reporting period, Ebos Group reported total debt of A$1.90B.

How much cash does Ebos Group have on hand?

Ebos Group reported A$239.09M in cash and cash equivalents in its most recent financial results.

What is Ebos Group’s dividend yield?

Ebos Group currently has a dividend yield of 6.23%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.